13F Data
13F filer · CIK 1559565

Sofinnova Management VIII, L.L.C.

Menlo Park, CA · filing since Q4 2016 · last filing Feb 14, 2018
Reported value
$183.2M
+$19.2M vs prior
Positions
8
New / sold out
0 / 0
Added / reduced
2 / 0
Turnover
0.0%
buys $50.2M · sells $0
Top-10 weight
100.0%

Biggest buys vs Q3 2017

ChangeSecurityShares changeChange %Est. trade value
AddedNuCana plc+4,000,000+600.0%+$40.4M
AddedObsEva SA+1,000,000+26.7%+$9.8M

Biggest sells vs Q3 2017

No reduced or sold positions this quarter.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2016: $177.7MQ1 2017: $189.6MQ2 2017: $178.4MQ3 2017: $164.0MQ4 2017: $183.2M
Q4 2016Q4 2017

Holdings · Q4 2017

#SecuritySharesValueWeight
1NuCana plcAMERICAN DEPOSITARY SHARES4,666,666$47.2M25.76%
2ObsEva SACOMMON STOCK4,749,623$46.4M25.31%
3Aclaris Therapeutics, Inc.COMMON STOCK1,539,480$38.0M20.72%
4Spark Therapeutics, Inc.COMMON STOCK481,270$24.7M13.51%
5Natera, Inc.COMMON STOCK1,550,280$13.9M7.61%
6Auris Medical Holding AGCOMMON SHARES7,818,175$4.6M2.52%
7Histogenics CorporationCOMMON STOCK2,077,040$4.3M2.32%
8Synlogic, Inc.COMMON STOCK424,972$4.1M2.25%